Age, prostate-specific antigen, screening frequency, and metastatic prostate cancer in U.S. Veterans

In a cohort study of over 100,000 U.S. Veterans, older age at first PSA test and longer screening intervals were significantly associated with a higher risk of metastatic prostate cancer, highlighting the potential for optimizing screening strategies to reduce late-stage diagnoses.

The Gist

The Big Picture: The "Prostate Health Radar"

Imagine the prostate gland as a small, quiet factory in a man's body. Sometimes, this factory starts producing "smoke signals" called PSA (Prostate-Specific Antigen). Doctors use a blood test to measure these smoke signals. If the signal is high, it's a warning flare that something might be wrong.

For a long time, there was a big debate: How often should we check these smoke signals?

• Too often? You might panic over harmless dust (overdiagnosis).
• Too rarely? You might miss a real fire until it's too big to put out (metastasis).

This study looked at over 100,000 U.S. Veterans to see how their "smoke signal" checking habits affected whether they got caught with a small, manageable fire or a massive, spreading blaze (metastatic cancer).

---

The Three Rules of the Game

The researchers looked at three specific things to see what made the biggest difference:

1. The Starting Line (Age): When did the man start getting checked? (Under 50, 50–59, or 60+?)
2. The Smoke Level (PSA Value): What was the number on the first test? (Low, medium, or high?)
3. The Check-Up Frequency (Interval): How long did they wait between tests? (Every 2 years or longer?)

The Findings: What the Data Told Us

Think of this like a weather forecast for cancer risk. The study found that waiting too long and starting too late were the biggest red flags.

1. The "Late Starter" Penalty

If a man waited until he was 60 or older to start his first check-up, he was much more likely to be diagnosed with cancer that had already spread (metastasis).

• Analogy: It's like waiting until your house is already on fire to buy a smoke detector. By the time you check, the damage is done. Starting early (under 50) gave them a much better chance of catching the problem while it was just a tiny spark.

2. The "Long Gap" Danger

Men who went more than 2 years between tests had a higher risk of metastatic cancer compared to those who checked every 2 years or less.

• Analogy: Imagine checking your car's oil only once every five years. If a small leak starts, you won't know until the engine seizes up. Checking every 2 years (or less) is like checking the oil every 6 months; you catch the leak before the engine blows.

3. The "High Smoke" Warning

Naturally, men who started with a high PSA number (above 4.0) had a much higher risk. But the study showed that even if your number was high, checking frequently helped manage the risk better than waiting.

The "Golden Ticket" Combination

The study found the specific group of men with the lowest risk of finding advanced cancer:

• Started checking early (under 50).
• Kept the gaps short (checked every 2 years or less).
• Had a moderate PSA number (not too low, not dangerously high).

The Metaphor: These men were like drivers who checked their tires every month, started driving at a young age, and noticed a slow leak immediately. They never had a blowout.

The "Veteran" Context

Why Veterans?

• The Population: Veterans often have higher exposure to certain risks (like Agent Orange) and face unique health challenges.
• The System: The VA (Veterans Affairs) is a massive, organized system. It's like a giant, well-connected network of hospitals. Because they all follow similar rules, the researchers could get a very clear picture of what works and what doesn't.

The Takeaway for Regular Folks

This study suggests that the "one-size-fits-all" approach to cancer screening might be outdated.

• Don't wait until you're 60: If you are at higher risk (like Black men or those with family history), starting your "smoke signal" checks in your 40s or early 50s could save your life.
• Don't skip a beat: Waiting 3, 4, or 5 years between checks is risky. A 2-year gap (or less) seems to be the sweet spot for catching trouble early.
• It's about the combo: It's not just about the number on the test; it's about when you took the test and how often you took it.

The Bottom Line

The researchers are saying: "We need to tune our radar." By starting earlier and checking more frequently, we can catch prostate cancer while it's still a small, manageable spark, rather than waiting until it becomes a raging fire that spreads across the body.

Note: This is a preprint study, meaning it's new research that hasn't been fully peer-reviewed yet, but it offers strong clues for how doctors might change screening rules in the future.

Technical Summary

1. Problem Statement

Prostate cancer (PCa) remains a leading cause of male cancer mortality in the U.S. Following the 2012 USPSTF recommendation against routine PSA screening, screening rates declined, leading to a documented rise in metastatic PCa incidence and a plateau in mortality reduction. While guidelines exist regarding when to start screening (age), how often to screen (interval), and what PSA thresholds to use, few studies have analyzed real-world screening patterns within large, integrated healthcare systems to determine how these specific parameters interact to influence the risk of metastatic disease at diagnosis. This is particularly critical for the Veteran population, who face unique risk factors (e.g., Agent Orange exposure) and often have higher baseline PCa rates.

2. Methodology

Study Design and Population

• Design: Retrospective cohort study.
• Data Source: Veterans Health Administration (VHA) corporate data warehouse and the VA Multi-OMICS Analysis Platform for Prostate Cancer (VA-MAPP).
• Cohort: 103,067 veterans diagnosed with a first prostate needle biopsy (PNBx) between 2015 and 2023.
• Inclusion/Exclusion: Included men with at least two VA visits (2005–2020) and at least one PSA test within 5 years prior to their first biopsy. Excluded men with a prior PCa diagnosis or no PSA history in the 5-year lookback period.
• Follow-up: Through 2024.

Exposures (PSA Screening Parameters)
The study evaluated three primary parameters categorized as follows:

1. Age at First PSA: <50, 50–59, and ≥60 years.
2. First PSA Value: ≤1, 1.01–2.50, 2.51–4, and >4 ng/mL.
3. Screening Interval: The longest gap between consecutive PSA tests in the 5 years prior to biopsy, dichotomized as ≤24 months vs. >24 months.
   • Note: Intervals were calculated starting at age 45 for Black veterans and age 55 for others, aligning with NCCN/AUA guidelines.

Outcomes

• Primary Outcome: Metastatic PCa (regional or distant) at the time of the first PNBx, identified via ICD-10 codes and the VHA Prostate Cancer Data Core metastasis flag.
• Comparators: Localized PCa and benign biopsy results.

Statistical Analysis

• Primary Analysis: Multivariable Cox proportional hazards models to estimate Hazard Ratios (HR) for metastatic PCa, adjusting for sociodemographic (race, ADI), clinical (BMI, Agent Orange exposure, service-connected disability), and screening covariates.
• Interaction Analysis: Modified Poisson regression models with robust variance were used to estimate Absolute Rates and Relative Rates (aRR) for combinations of screening factors (e.g., Age × PSA value, Age × Interval).
• Sensitivity Analysis: Inverse Probability of Censoring Weights (IPCW) were applied to a larger pseudopopulation (n=11.2 million) to correct for potential selection bias induced by restricting the cohort to men who underwent biopsy.

3. Key Results

Cohort Characteristics

• Demographics: 31% Non-Hispanic Black, 57% Non-Hispanic White. 20% were <50 years old at their first PSA.
• Diagnosis Distribution: 3.7% Metastatic PCa, 44.8% Localized PCa, 51.6% Benign.
• Risk Factors: Metastatic cases were significantly older at first PSA, had higher rates of severe service-connected disability, and were more likely to have longer screening intervals (>24 months).

Associations with Metastatic Disease

• Age: Older age at first PSA was strongly associated with metastatic risk. Compared to <50 years, the adjusted Hazard Ratio (aHR) was 1.08 (50–59 yrs) and 1.79 (≥60 yrs).
• Screening Interval: Longer intervals (>24 months) were associated with a 9% increased risk of metastatic PCa (aHR 1.09) compared to intervals ≤24 months.
• PSA Value: Higher initial PSA values were the strongest predictor. PSA >4 ng/mL had an aHR of 8.11 compared to ≤1 ng/mL.

Interaction Effects (Combined Risk Stratification)
The study identified specific combinations of factors that yielded the lowest risk:

• Lowest Risk Group: Veterans aged <50 years with a first PSA of 1.01–2.50 ng/mL and a screening interval ≤24 months.
  • Relative Risk (aRR) compared to the highest risk group (Age ≥60, Interval >24mo, PSA >4): 0.10 (95% CI: 0.09–0.12).
• High Risk Group: Veterans aged ≥60 with intervals >24 months and PSA >4 ng/mL served as the reference for highest risk.
• Nuance: Among those with long intervals (>24 months), men with very low initial PSA (≤1 ng/mL) had higher risk than those with moderate PSA (1.01–2.50 ng/mL), suggesting a potential "delayed diagnosis" effect where low initial values led to infrequent monitoring, allowing aggressive disease to progress undetected.

Sensitivity Analysis
The IPCW analysis confirmed that selection bias did not drive the primary findings; results remained consistent with slight attenuation for age and slight elevation for PSA value.

4. Key Contributions

1. Granular Risk Stratification: Unlike previous studies that looked at screening parameters in isolation, this study quantifies the joint effects of age, PSA value, and screening frequency. It demonstrates that the combination of early screening (younger age), moderate initial PSA, and frequent monitoring yields the most favorable outcomes regarding metastasis.
2. Real-World Evidence in a High-Risk Cohort: Utilizing a massive, diverse veteran cohort (including high rates of Black veterans and Agent Orange exposure) provides robust data on how screening guidelines perform in a population with elevated baseline risk.
3. Identification of the "Lowest Risk" Profile: The study empirically identifies that the most favorable screening profile is not just "frequent screening," but specifically screening initiated at a younger age (<50) with a moderate PSA baseline (1.01–2.50) and short intervals.
4. Evidence for Interval Optimization: The data supports the guideline recommendation of ≤24-month intervals, showing a statistically significant increase in metastatic risk when gaps exceed this threshold.

5. Significance and Implications

• Optimizing Screening Guidelines: The findings suggest that current "shared decision-making" models may need to be more prescriptive for high-risk groups (e.g., Black veterans, those with Agent Orange exposure). The data supports initiating screening earlier (age <50) and maintaining shorter intervals (≤24 months) to minimize metastatic presentation.
• Addressing Disparities: Given the higher prevalence of metastatic disease in Black veterans and those with service-connected disabilities, these results argue for tailored, more aggressive screening strategies for these subpopulations rather than a "one-size-fits-all" approach.
• Clinical Practice: The study highlights that a "low" initial PSA does not guarantee safety if screening intervals are too long; clinicians must balance initial values with the frequency of follow-up to prevent delayed diagnosis of aggressive disease.
• Future Modeling: The authors propose that these risk stratification patterns can serve as inputs for modeling studies to calculate the precise harm-benefit tradeoffs (e.g., overtreatment vs. metastasis prevention) of different screening algorithms.

Limitations: The study is limited to VA data (potentially missing non-VA PSA tests), relies on administrative coding, and may suffer from selection bias regarding who undergoes biopsy, though sensitivity analyses mitigated this concern. Generalizability to the non-veteran U.S. population requires further validation.